AstraZeneca's Zactima lung-cancer trials meet primary endpoint

By Elaine Rigoli

Tampa, Fla., June 7 - AstraZeneca said its two phase 2 studies, Trial 003 and 006, with Zactima, met their primary endpoints of progression-free survival.

Zactima (ZD6474) is a compound that targets both epidermal growth factor receptor and vascular endothelial growth factor receptor cell signaling pathways, the company said in a news release.

"Lung cancer is not a single entity but rather a heterogeneous disease making it difficult to treat. The potential to selectively target multiple key signaling pathways involved in tumor growth with investigational agents may provide an additional benefit to patients suffering from lung cancer," study investigator Roy Herbst said in the release.

AstraZeneca is an international health care business located in Wilmington, Del.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.